J 2012

Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma

SZTURZ, Petr, Zdeněk ŘEHÁK, Renata KOUKALOVÁ, Zdeněk ADAM, Marta KREJČÍ et. al.

Basic information

Original name

Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ŘEHÁK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Jiří VANÍČEK (203 Czech Republic, belonging to the institution), Tomáš NEBESKÝ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Nuclear Medicine and Biology, 2012, 0969-8051

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.517

RIV identification code

RIV/00216224:14110/12:00059813

Organization unit

Faculty of Medicine

UT WoS

000301961700012

Keywords in English

Langerhans cell histiocytosis; Interstitial lung disease; Positron emission tomography; Pulmonary function tests; High-resolution computed tomography (HRCT)

Tags

International impact
Změněno: 1/10/2018 11:58, Soňa Böhmová

Abstract

V originále

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare cause of interstitial lung disease characterized by formation of nodules in the active phase of the disease that evolve into nonactive cystic lesions later on. To evaluate PLCH activity in patients, we developed a new method for measuring diffuse metabolic activity on fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography (FDG-PET/CT) using a lung-to-liver activity ratio. Material and Methods: We retrospectively studied a series of 4 FDG-PET and 23 FDG-PET/CT scans from 7 patients with PLCH and analyzed a sample of 100 randomly chosen FDG-PET/CT studies free from any known lung or hepatic diseases. Maximum standardized uptake value (SUVmax) in a spherical volume (6–8 cm in diameter) in the right lung was put into relation with SUVmax in a spherical volume (9–10 cm in diameter) in the reference liver parenchyma to set up the SUVmaxPULMO/SUVmaxHEPAR index. The index values were compared to the disease course in each patient. Results: In patients with PLCH, a close correlation between the index value and the disease course was found in all seven subjects, where the increasing index values indicated disease activity, while decreasing index values were observed after therapy administration. In the group of 100 healthy control subjects, we found index values lower than 0.3 in 80% and lower than 0.4 in 96%. Conclusion: Measuring SUVmaxPULMO/SUVmaxHEPAR values and their time-trend monitoring represent simple, noninvasive screening tools allowing an early diagnosis and treatment response follow-up assessment in patients with PLCH.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NS9671, research and development project
Name: Stanovení hladiny cytokinů a kostimulačních molekul v plasmě, kostní dřeni, leukocytech a nádorových buňkách nemocných s hematologickými malignitami a jejich vztah k aktivitě nemoci, transplantaci krvetvorby, rozvoji komplikací (GvHD) a riziku relapsu.
Investor: Ministry of Health of the CR
NT11154, research and development project
Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR

Files attached